
Over the last 7 days, the Clinical Research and Equipment industry has dropped 3.3%, driven by Locus Cell declining 9.4%. The industry has fallen 5.5% in the last year.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 16 Jun 2026 | NT$31.4b | NT$2.7b | -NT$747,832,000.00 | 21.5x | -41.9x | 11.8x |
| Thu, 14 May 2026 | NT$33.2b | NT$2.5b | -NT$764,028,000.00 | 21.5x | -43.5x | 13.2x |
| Sat, 11 Apr 2026 | NT$31.1b | NT$2.5b | -NT$767,980,000.00 | 21.8x | -40.5x | 12.4x |
| Mon, 09 Mar 2026 | NT$32.5b | NT$2.4b | -NT$692,870,000.00 | 19.5x | -46.9x | 13.4x |
| Wed, 04 Feb 2026 | NT$33.2b | NT$2.4b | -NT$689,929,000.00 | 23.9x | -48.1x | 13.7x |
| Fri, 02 Jan 2026 | NT$33.9b | NT$2.4b | -NT$689,929,000.00 | 25.8x | -49.2x | 14x |
| Sun, 30 Nov 2025 | NT$37.9b | NT$2.4b | -NT$670,921,000.00 | 19.9x | -56.5x | 15.5x |
| Tue, 28 Oct 2025 | NT$36.3b | NT$2.5b | -NT$870,437,000.00 | 18.5x | -41.7x | 14.8x |
| Thu, 25 Sep 2025 | NT$35.3b | NT$2.5b | -NT$870,437,000.00 | 19.8x | -40.5x | 14.4x |
| Sat, 23 Aug 2025 | NT$35.6b | NT$2.5b | -NT$819,216,000.00 | 20.6x | -43.5x | 14.5x |
| Mon, 21 Jul 2025 | NT$34.4b | NT$2.5b | -NT$600,003,000.00 | 22.3x | -57.4x | 14x |
| Wed, 18 Jun 2025 | NT$32.9b | NT$2.5b | -NT$600,003,000.00 | 23.5x | -54.9x | 13.4x |
| Fri, 16 May 2025 | NT$31.8b | NT$2.5b | -NT$604,301,000.00 | 23.3x | -52.6x | 13x |
| Sun, 13 Apr 2025 | NT$30.7b | NT$2.5b | -NT$540,128,000.00 | 23.4x | -56.9x | 12.5x |
| Tue, 11 Mar 2025 | NT$36.3b | NT$2.6b | -NT$854,432,000.00 | 24.6x | -42.5x | 14.2x |
| Thu, 06 Feb 2025 | NT$37.2b | NT$2.6b | -NT$854,432,000.00 | 24x | -43.5x | 14.5x |
| Sat, 04 Jan 2025 | NT$34.5b | NT$2.6b | -NT$854,432,000.00 | 22.8x | -40.4x | 13.5x |
| Mon, 02 Dec 2024 | NT$42.2b | NT$2.6b | -NT$854,432,000.00 | 23.7x | -49.4x | 16.5x |
| Wed, 30 Oct 2024 | NT$42.1b | NT$2.5b | -NT$712,402,000.00 | 24.5x | -59x | 16.7x |
| Fri, 27 Sep 2024 | NT$41.2b | NT$2.3b | -NT$836,610,000.00 | 22.3x | -49.3x | 18.1x |
| Sun, 25 Aug 2024 | NT$40.9b | NT$2.3b | -NT$836,610,000.00 | 22.3x | -48.9x | 18x |
| Tue, 23 Jul 2024 | NT$42.7b | NT$2.1b | -NT$797,765,000.00 | 33.2x | -53.5x | 20x |
| Thu, 20 Jun 2024 | NT$41.5b | NT$2.1b | -NT$797,765,000.00 | 34.3x | -52x | 19.4x |
| Sat, 18 May 2024 | NT$40.7b | NT$2.1b | -NT$893,893,000.00 | 32.1x | -45.6x | 19.1x |
| Mon, 15 Apr 2024 | NT$40.9b | NT$2.1b | -NT$903,875,000.00 | 30.9x | -45.3x | 19.4x |
| Wed, 13 Mar 2024 | NT$40.5b | NT$2.1b | -NT$611,249,000.00 | 32.8x | -66.3x | 19.7x |
| Fri, 09 Feb 2024 | NT$43.0b | NT$2.1b | -NT$610,218,000.00 | 32.4x | -70.4x | 20.7x |
| Sun, 07 Jan 2024 | NT$46.5b | NT$2.1b | -NT$610,218,000.00 | 34.4x | -76.3x | 22.4x |
| Tue, 05 Dec 2023 | NT$49.7b | NT$2.1b | -NT$610,218,000.00 | 34.9x | -81.4x | 23.9x |
| Thu, 02 Nov 2023 | NT$49.0b | NT$2.2b | -NT$497,769,000.00 | 31.6x | -98.5x | 22x |
| Sat, 30 Sep 2023 | NT$48.0b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -96.4x | 21.6x |
| Mon, 28 Aug 2023 | NT$43.1b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -86.7x | 19.4x |
| Wed, 26 Jul 2023 | NT$49.0b | NT$2.5b | -NT$274,767,000.00 | 42.3x | -178.2x | 20x |
| Fri, 23 Jun 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 43.2x | -176.1x | 19.7x |
-176.1x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 4.30% | |
| Healthcare | 0.84% | |
| Life Sciences | -2.23% | |
| Clinical Research and Equipment | -2.23% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 7607 DuoGenic StemCells | NT$14.40 | 8.7% +NT$35.1m | 41.2% | n/a | |
| 6848 RBC Bioscience | NT$20.50 | 5.1% +NT$14.3m | 24.6% | PE12.4x | |
| 6662 BioLASCO Taiwan | NT$29.90 | 0.7% +NT$5.1m | -11.4% | PE18x |